Cerus (CERS) Stifel 2024 Healthcare Conference summary

Industry context and market overview

• Transfusion medicine remains a niche but critical field, with ongoing threats from emerging pathogens like Oropouche and monkeypox.

• INTERCEPT technology is now standard of care in multiple countries, with expansion ongoing in about 40 countries.

• The global addressable market for approved products exceeds $2.5 billion, with total potential over $7 billion.

• Demand for blood components grows organically at mid-single digits annually, driven by evolving medical care.

• Policy changes and operational benefits are key adoption drivers, alongside regulatory mandates.

U.S. platelet market dynamics

• U.S. platelet market has grown from $150 million to $200 million, with mid-single digit annual growth.

• Growth is driven by advances in oncology, trauma, and cardiovascular care, increasing platelet demand.

• Top five blood centers control 75% of supply; Red Cross has 100% adoption, others range from 15%-85%.

• Barriers to further adoption include supply constraints and economic considerations.

• Shelf life extension to seven days could materially impact adoption, pending further FDA-required studies.

International expansion and regulatory progress

• EMEA, Middle East, and LATAM are key near-term international growth targets, with Germany and Brazil highlighted.

• China represents the largest future market; regulatory approval and reimbursement processes are underway.

• Hong Kong data supports China approval; commercial rollout will target top provincial centers post-approval.